Titre : Hétérochromatine

Hétérochromatine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Microarray Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hétérochromatine : Questions médicales les plus fréquentes", "headline": "Hétérochromatine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hétérochromatine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-24", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hétérochromatine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Chromatine", "url": "https://questionsmedicales.fr/mesh/D002843", "about": { "@type": "MedicalCondition", "name": "Chromatine", "code": { "@type": "MedicalCode", "code": "D002843", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.160.180" } } }, "about": { "@type": "MedicalCondition", "name": "Hétérochromatine", "alternateName": "Heterochromatin", "code": { "@type": "MedicalCode", "code": "D006570", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Weiqi Zhang", "url": "https://questionsmedicales.fr/author/Weiqi%20Zhang", "affiliation": { "@type": "Organization", "name": "University of Chinese Academy of Sciences, Beijing 100049, China." } }, { "@type": "Person", "name": "Guang-Hui Liu", "url": "https://questionsmedicales.fr/author/Guang-Hui%20Liu", "affiliation": { "@type": "Organization", "name": "University of Chinese Academy of Sciences, Beijing 100049, China." } }, { "@type": "Person", "name": "Moshi Song", "url": "https://questionsmedicales.fr/author/Moshi%20Song", "affiliation": { "@type": "Organization", "name": "University of Chinese Academy of Sciences, Beijing 100049, China." } }, { "@type": "Person", "name": "Jing Qu", "url": "https://questionsmedicales.fr/author/Jing%20Qu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China." } }, { "@type": "Person", "name": "Qianzhao Ji", "url": "https://questionsmedicales.fr/author/Qianzhao%20Ji", "affiliation": { "@type": "Organization", "name": "University of Chinese Academy of Sciences, Beijing 100049, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prenatal diagnosis of fetuses conceived by assisted reproductive technology by karyotyping and chromosomal microarray analysis.", "datePublished": "2023-01-17", "url": "https://questionsmedicales.fr/article/36684682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.14678" } }, { "@type": "ScholarlyArticle", "name": "Chromosome microarray analysis combined with karyotype analysis is a powerful tool for the detection in pregnant women with high-risk indicators.", "datePublished": "2023-11-11", "url": "https://questionsmedicales.fr/article/37951870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-023-06052-z" } }, { "@type": "ScholarlyArticle", "name": "Saliva DNA: An alternative biospecimen for single nucleotide polymorphism chromosomal microarray analysis in autism.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37715344", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ajmg.a.63400" } }, { "@type": "ScholarlyArticle", "name": "Fetal congenital gastrointestinal obstruction: prenatal diagnosis of chromosome microarray analysis and pregnancy outcomes.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37422671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-023-05828-7" } }, { "@type": "ScholarlyArticle", "name": "Genetic causes of isolated and severe fetal growth restriction in normal chromosomal microarray analysis.", "datePublished": "2023-01-02", "url": "https://questionsmedicales.fr/article/36495297", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijgo.14620" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Structures de chromosome", "item": "https://questionsmedicales.fr/mesh/D022004" }, { "@type": "ListItem", "position": 5, "name": "Chromatine", "item": "https://questionsmedicales.fr/mesh/D002843" }, { "@type": "ListItem", "position": 6, "name": "Hétérochromatine", "item": "https://questionsmedicales.fr/mesh/D006570" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hétérochromatine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hétérochromatine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hétérochromatine", "description": "Comment diagnostiquer l'hétérochromatine ?\nQuels tests sont utilisés pour l'hétérochromatine ?\nL'hétérochromatine est-elle visible au microscope ?\nPeut-on détecter l'hétérochromatine par IRM ?\nQuels marqueurs sont associés à l'hétérochromatine ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hétérochromatine", "description": "Quels symptômes sont liés à des anomalies d'hétérochromatine ?\nL'hétérochromatine affecte-t-elle la santé mentale ?\nY a-t-il des signes cliniques d'hétérochromatine ?\nL'hétérochromatine est-elle liée à des maladies ?\nPeut-on observer des symptômes physiques ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hétérochromatine", "description": "Peut-on prévenir les anomalies d'hétérochromatine ?\nY a-t-il des facteurs environnementaux à éviter ?\nL'alimentation influence-t-elle l'hétérochromatine ?\nLe stress a-t-il un impact sur l'hétérochromatine ?\nDes examens réguliers peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hétérochromatine", "description": "Quels traitements existent pour les anomalies d'hétérochromatine ?\nL'hétérochromatine peut-elle être modifiée ?\nDes médicaments peuvent-ils affecter l'hétérochromatine ?\nY a-t-il des essais cliniques sur l'hétérochromatine ?\nComment l'hétérochromatine est-elle ciblée en thérapie ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hétérochromatine", "description": "Quelles complications peuvent survenir avec l'hétérochromatine ?\nL'hétérochromatine est-elle liée à des cancers spécifiques ?\nPeut-elle affecter la fertilité ?\nY a-t-il des risques pour la descendance ?\nDes troubles neurologiques peuvent-ils être liés ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hétérochromatine", "description": "Quels sont les facteurs de risque pour l'hétérochromatine ?\nL'âge influence-t-il l'hétérochromatine ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles affecter l'hétérochromatine ?\nY a-t-il un lien avec des maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D006570?mesh_terms=Microarray+Analysis&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hétérochromatine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par microscopie et analyse de l'ADN pour identifier la structure chromosomique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'hétérochromatine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de coloration chromosomique et des techniques de séquençage peuvent être utilisés." } }, { "@type": "Question", "name": "L'hétérochromatine est-elle visible au microscope ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hétérochromatine apparaît comme des zones sombres sur les chromosomes lors de l'observation." } }, { "@type": "Question", "name": "Peut-on détecter l'hétérochromatine par IRM ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'IRM ne peut pas détecter l'hétérochromatine, car elle analyse des tissus, pas des chromosomes." } }, { "@type": "Question", "name": "Quels marqueurs sont associés à l'hétérochromatine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme H3K9me3 et H3K27me3 sont souvent utilisés pour identifier l'hétérochromatine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à des anomalies d'hétérochromatine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent entraîner des troubles génétiques, mais souvent, il n'y a pas de symptômes visibles." } }, { "@type": "Question", "name": "L'hétérochromatine affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'hétérochromatine et certains troubles neurodéveloppementaux." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques d'hétérochromatine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de signes cliniques spécifiques, mais des anomalies chromosomiques peuvent être observées." } }, { "@type": "Question", "name": "L'hétérochromatine est-elle liée à des maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le cancer peuvent être associées à des modifications de l'hétérochromatine." } }, { "@type": "Question", "name": "Peut-on observer des symptômes physiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes physiques dépendent des maladies associées, pas directement de l'hétérochromatine." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies d'hétérochromatine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques génétiques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines et à des radiations peut affecter la structure de l'hétérochromatine." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle l'hétérochromatine ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en nutriments peut soutenir la santé génétique et potentiellement l'hétérochromatine." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur l'hétérochromatine ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut influencer les modifications épigénétiques, y compris l'hétérochromatine." } }, { "@type": "Question", "name": "Des examens réguliers peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des examens réguliers peuvent aider à détecter des anomalies génétiques précoces, mais pas spécifiquement l'hétérochromatine." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies d'hétérochromatine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique, mais des thérapies géniques peuvent être envisagées." } }, { "@type": "Question", "name": "L'hétérochromatine peut-elle être modifiée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sur les modifications épigénétiques montrent que l'hétérochromatine peut être ciblée." } }, { "@type": "Question", "name": "Des médicaments peuvent-ils affecter l'hétérochromatine ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent influencer les modifications épigénétiques de l'hétérochromatine." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur l'hétérochromatine ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques explorent des traitements ciblant les anomalies d'hétérochromatine." } }, { "@type": "Question", "name": "Comment l'hétérochromatine est-elle ciblée en thérapie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme l'édition génomique visent à corriger les anomalies d'hétérochromatine." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'hétérochromatine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles génétiques et un risque accru de cancer." } }, { "@type": "Question", "name": "L'hétérochromatine est-elle liée à des cancers spécifiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines formes de cancer, comme le cancer du sein, montrent des anomalies d'hétérochromatine." } }, { "@type": "Question", "name": "Peut-elle affecter la fertilité ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies d'hétérochromatine peuvent influencer la fertilité, mais cela dépend des cas individuels." } }, { "@type": "Question", "name": "Y a-t-il des risques pour la descendance ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'hétérochromatine peuvent être transmises et affecter la santé des descendants." } }, { "@type": "Question", "name": "Des troubles neurologiques peuvent-ils être liés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre l'hétérochromatine et des troubles neurologiques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'hétérochromatine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux de maladies génétiques et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge influence-t-il l'hétérochromatine ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la structure et la fonction de l'hétérochromatine." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain, comme le tabagisme, peut augmenter le risque d'anomalies chromosomiques." } }, { "@type": "Question", "name": "Les infections peuvent-elles affecter l'hétérochromatine ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent influencer les modifications de l'hétérochromatine." } }, { "@type": "Question", "name": "Y a-t-il un lien avec des maladies auto-immunes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent être associées à des anomalies d'hétérochromatine." } } ] } ] }

Sources (10000 au total)

Prenatal diagnosis of fetuses conceived by assisted reproductive technology by karyotyping and chromosomal microarray analysis.

Invasive prenatal evaluation by chromosomal microarray analysis (CMA) and karyotyping might represent an important option in pregnant women, but limited reports have applied CMA and karyotyping of fet... This retrospective study included all singleton fetuses conceived by ART from January 2015 to December 2021. Anomalies prenatally diagnosed based on karyotyping and CMA were analyzed. Prevalence rates... In total, 224 subjects were assessed by karyotyping and CMA. In the examined patients, chromosomal and karyotype abnormality rates were 3.57% (8/224) and 8.93% (20/224), respectively. This finding ind... Prenatal diagnosis including karyotyping and CMA is recommended for fetuses conceived by ART, with or without ultrasound findings....

Chromosome microarray analysis combined with karyotype analysis is a powerful tool for the detection in pregnant women with high-risk indicators.

Karyotype analysis and fluorescence in situ hybridization (FISH) are commonly used for prenatal diagnosis, however they have many disadvantages. Chromosome microarray analysis (CMA) has the potential ... A total of 3336 samples of amniotic fluid or umbilical cord blood from pregnant women with high-risk indicators at our center in southwest of China from June 2018 to January 2023 were included in the ... 3336 samples divided into 2911 cases with single and 425 cases with multiple high-risk indicators. The aneuploidy and pathogenic/likely pathogenic copy number variations (CNVs) of 2911 cases with sing... The combined application of CMA and karyotyping were recommended in prenatal diagnosis for providing a scientific and accurate genetic diagnosis and improving the quality of prenatal genetic counselin...

Fetal congenital gastrointestinal obstruction: prenatal diagnosis of chromosome microarray analysis and pregnancy outcomes.

The aim of this study was to investigate the incidence of chromosome anomalies in different types of congenital gastrointestinal obstruction and assess pregnancy outcomes of fetuses with congenital ga... A total of 64 cases with gastrointestinal obstruction between January 2014 and December 2020 were enrolled in this study. They were divided into three groups according to sonographic images. Group A: ... From January 2014 to December 2020, there were 64 fetus with congenital gastrointestinal obstruction underwent chromosome microarray analysis(CMA), the overall detection rate of CMA testing was 14.1%(... It is crucial to understand whether the gastrointestinal tract abnormality is isolated or associated to other findings. The risk of chromosomal abnormalities in fetuses with isolated lower gastrointes...

Genetic causes of isolated and severe fetal growth restriction in normal chromosomal microarray analysis.

To investigate the genetic burden in fetuses with isolated and severe fetal growth restriction (FGR) using Trio whole-exome sequencing (WES) with a normal chromosomal microarray.... This retrospective study analyzed WES results of singleton fetuses with isolated and severe FGR, whose estimated fetal weight (EFW) was less than the third percentile by Hadlock formula, in a tertiary... Fifty-one fetuses with isolated and severe FGR and negative CMA results underwent Trio-WES. Of all patients, eight (15.7%) were diagnosed with FGR at its early onset (<32 weeks) and showed pathogenic ... The present study indicates that Trio-WES can improve effectivity of prenatal diagnoses for isolated and severe FGR in cases with normal CMA results, aiding prenatal genetic counseling and pregnancy m...

Prenatal diagnosis of chromosomal aberrations by chromosomal microarray analysis and pregnancy outcomes of fetuses with polyhydramnios.

To explore the prenatal clinical utility of chromosome microarray analysis (CMA) for polyhydramnios and evaluate the short and long-term prognosis of fetuses with polyhydramnios.... A total of 600 singleton pregnancies with persistent polyhydramnios from 2014 to 2020 were retrospectively enrolled in this study. All cases received amniocentesis and were subjected to CMA results. A... The detection rates of either aneuploidy or pathogenic copy number variants in fetuses with non-isolated polyhydramnios were significantly higher than those with isolated polyhydramnios (5.0... For low-risk pregnancies, invasive prenatal diagnosis of isolated polyhydramnios might be unnecessary. CMA should be considered for fetuses with structural anomalies. In CMA-negative cases, the progno...

Chromosomal microarray analysis versus noninvasive prenatal testing in fetuses with increased nuchal translucency.

To evaluate if the NT value of 2.5 mm ≤ NT < 3.0 mm is an appropriate indication for CMA tests among fetuses with isolated increased NT and NIPT is more suitable instead.... A total of 442 fetuses with NT ≥ 2.5 mm were included, in which 241 fetuses underwent karyotype. CMA tests were then carried out when cytogenic analysis showed normal chromosomes and CNV status was co... Of the 241 fetuses with NT ≥ 2.5 mm, 47(19.50%) were identified by karyotype with chromosomal abnormalities. Among 194 cases with normal karyotype, CMA unraveled additional CNVs in 16(8.25%) cases, in... While no pathogenic CNVs were detected in fetuses, chromosomal aneuploidies and genomic imbalance were found to be the major type of abnormalities when NT was 2.5-3.0 mm. Therefore, our data suggested...

Integrated multiple-microarray analysis and mendelian randomization to identify novel targets involved in diabetic nephropathy.

Diabetic nephropathy (DN), which is the main cause of renal failure in end-stage renal disease, is becoming a common chronic renal disease worldwide. Mendelian randomization (MR) is a genetic tool tha... Five DN gene expression datasets were selected from the Gene Expression Omnibus. The robust rank aggregation (RRA) method was used to integrate differentially expressed genes (DEGs) of glomerular samp... A total of 82 DEGs (53 upregulated and 29 downregulated) were identified through RRA integrated analysis. The enriched Gene Ontology annotations and Kyoto Encyclopedia of Genes and Genomes pathways of... Our integrated analysis identified novel biomarkers, including MICB and GZMA, which may help further understand the complicated mechanisms of DN and identify new target pathways for intervention....